Table 2.
Proteins identified to decrease after tocilizumab treatment.
| Protein name | Accession no. | Times of detection | Relative abundance (average) | Decrease ratio | Paired t-test P | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| ctr | Before | 4W | 8W | Before/4W | Before/8W | Before versus 4W | Before versus 8W | |||
| C-reactive protein, pentraxin-related | 55770842 | 5 | 1 | 13.507 | 4.107 | 2.124 | 17.928 | 15.085 | 0.252 | 0.037 |
| Orosomucoid 1 precursor | 167857790 | 6 | 1 | 6.130 | 1.725 | 0.775 | 13.070 | 7.750 | 0.124 | 0.041 |
| Haptoglobin isoform 1 preproprotein | 4826762 | 7 | 1 | 2.876 | 1.028 | 0.507 | 7.261 | 5.266 | 0.067 | 0.015 |
| Serine proteinase inhibitor, clade A, member 1 | 50363221 | 7 | 1 | 3.278 | 1.403 | 1.025 | 3.974 | 3.318 | 0.051 | 0.008 |
| Pregnancy-zone protein | 162809334 | 7 | 1 | 1.592 | 0.755 | 0.633 | 2.126 | 2.966 | 0.010 | 0.009 |
| Complement component 9 precursor | 4502511 | 7 | 1 | 1.979 | 1.194 | 1.307 | 1.713 | 1.631 | 0.012 | 0.015 |
| Leucine-rich alpha-2-glycoprotein 1 | 16418467 | 7 | 1 | 2.636 | 1.681 | 1.735 | 1.803 | 1.597 | 0.012 | 0.013 |
Accession number: accession number (gi) in the human RefSeq protein database of the National Center for Biotechnology Information, USA.
Times of detection: the number of samples in which the protein was detected.
Relative abundance: the ratio of the iTRAQ reporter ion to the 114 reporter ion (control).
Decrease ratio: the ratio of protein abundance between the first and seconed samples (Before/4W) and between the first and third samples (Before/8W).
Bold: increased by more than 1.5-fold.
Paired t-test P: the P value of a paired t-test between the first and second samples (4W) or between the first and third samples (8W).
Bold: P < 0.05.